Upon the start of using antidepressants, many clinicians will note that sometimes the sudden onset of suicidal ideation may accompany treatment. This has caused the Food and Drug Administration (FDA) to issue a warning stating that sometimes the use of antidepressants may actually increase suicidal ideation. Medical studies have found antidepressants help treat cases of suicidal ideation and work especially well with psychological therapy. Lithium reduces the risk of suicide in people with mood disorders. Tentative evidence finds clozapine in people with schizophrenia reduces the risk of suicide. See also
Existential angst
Existential crisis
Existential nihilism
Finno-Ugrian suicide hypothesis
Mental health first aid
Suicide attempt
Suicide crisis

References
Further reading
Beck, AT; Steer, RA; Kovacs, M; Garrison, B (1985). "Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation". Am J Psychiatry. 142 (5): 559–563. CiteSeerX 10.1.1.462.6328. doi:10.1176/ajp.142.5.559. PMID 3985195. Uncapher, H (2000–2001). "Cognitive biases and suicidal ideation in elderly psychiatric inpatients". Omega. 42 (1): 21–36. doi:10.2190/6uu8-hk8e-hl0v-q4cu. S2CID 144242247. Uncapher, H; Gallagher-Thompson, D; Osgood, NJ (1998). "Hopelessness and suicidal ideation in older adults". The Gerontologist. 38 (1): 62–70. doi:10.1093/geront/38.1.62. PMID 9499654. External links

Evaluation and Treatment of Patients with Suicidal Ideation Archived 2006-09-25 at the Wayback Machine
Suicidal Thought Archived 2014-07-02 at the Wayback Machine
National Suicide Prevention Lifeline: Warning signs Archived 2016-04-08 at the Wayback Machine
The pharmaceutical company Bristol-Myers Squibb manufactures the drug under the trade name Zerit.It is also the first drug to be granted parallel track status in 1992, by the US Food and Drug Administration (FDA), which allowed for the agency to make Stavudine available to patients before being approved. Stavudine was submitted under the FDAs accelerated approval process. Through this process, Stavudines effectiveness was measured by its effect on the surrogate marker, CD4, instead of clinical endpoints. The FDA concluded that an increase in CD4 cell counts was an indicator of how effective the drug would be against AIDS and HIV infection. Stavudine was the fourth drug to be approved for the treatment of AIDS and HIV infection by the FDA on June 27, 1994. Even after approval, studies were continued to evaluate the clinical benefit of the drug. If there is no indication of clinical benefits, the accelerated approval may be withdrawn.In 2018, Mylan Pharmaceuticals discontinued manufacturing stavudine 20 mg, 30 mg, and 40 mg capsules. References
External links
"Stavudine". Drug Information Portal. U.S. National Library of Medicine.